(RTTNews) – Dogwood Therapeutics, Inc. (DWTX), a development-stage biotechnology firm, introduced on Monday the top-line information from the just lately accomplished BHC IMC-2 Lengthy-COVID research.
In keeping with the corporate, IMC-2 therapy, dosed as valacyclovir 750 mg + celecoxib 200 mg twice day by day, demonstrated a clinically significant discount in long-term COVID-related fatigue and sleep disturbance as in comparison with placebo.
The research was carried out by way of an investigator-initiated, investigational analysis grant offered to the Bateman Horne Heart.
“Thus far, there aren’t any FDA-approved medicines to deal with Lengthy-COVID signs,” mentioned Lucinda Bateman, MD, Founder and Chief Medical Officer of the Bateman Horne Heart and the research’s principal investigator. “This trial supplies proof that IMC-2 has the potential to enhance fatigue and sleep signs related to Lengthy-COVID sickness on a scale not beforehand noticed in Lengthy-COVID analysis. I imagine this discovering warrants additional investigation of IMC-2 in bigger scale, multi-center Lengthy-COVID research.”
“The first objectives of this trial have been to find out the IMC-2 therapy impact dimension versus placebo and the related affected person pattern dimension to design our deliberate IMC-2 Section 2 Lengthy-COVID research in a way that maximizes likelihood of success,” mentioned R. Michael Gendreau, MD, Chief Medical Officer of Dogwood Therapeutics, Inc. “IMC-2 demonstrated a strong discount in fatigue, the first endpoint agreed with the Meals & Drug Administration to advance IMC-2 into Section 2 growth. We stay up for finalizing these plans and offering additional info on subsequent steps within the coming months.”
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
